New oral drug trial offers hope for rare skin disease
NCT ID NCT06444399
Summary
This study is testing whether an oral medication called deucravacitinib is safe and effective for treating pityriasis rubra pilaris (PRP), a rare inflammatory skin condition. It will enroll 12 adults with moderate-to-severe PRP to see if the drug improves their skin symptoms and quality of life over 24 weeks. The goal is to control the disease and reduce its impact, not to provide a permanent cure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITYRIASIS RUBRA PILARIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Conditions
Explore the condition pages connected to this study.